RT Journal Article
T1 Sex Differences in Plasma Lysophosphatidic Acid Species in Patients with Alcohol and Cocaine Use Disorders
A1 Flores López, María
A1 García Marchena, Nuria
A1 Araos, Pedro
A1 Requena Ocaña, Nerea
A1 Porras Perales, Oscar
A1 Torres Galván, Sandra
A1 Suarez, Juan
A1 Pizarro, Nieves
A1 Torre, Rafael de la
A1 Rubio, Gabriel
A1 Ruiz Ruiz, Juan Jesús
A1 Rodríguez De Fonseca, Fernando Antonio
A1 Serrano, Antonia
A1 Pavón Morón, Francisco Javier
AB Preclinical evidence suggests a main role of lysophosphatidic acid (LPA) signaling in drug addiction. Recently, we reported alterations in the plasma concentrations of LPA species in patients with alcohol use disorder (AUD). As there are sex differences in drug addiction, the main aim of the present study was to investigate whether relevant LPA species (16:0-LPA, 18:0-LPA, 18:1-LPA, 18:2-LPA and 20:4-LPA) were associated with sex and/or substance use disorder (SUD). This exploratory study was conducted in 214 abstinent patients with lifetime SUD, and 91 healthy control subjects. The SUD group was divided according to the diagnosis of AUD and/or cocaine use disorder (CUD). Participants were clinically assessed, and plasma samples were collected to determine LPA species and total LPA. We found that LPA concentrations were significantly affected by sex, and women showed higher concentrations than men. In addition, there were significantly lower 16:0-LPA, 18:2-LPA and total LPA concentrations in patients with SUD than in controls. Namely, patients with CUD and AUD + CUD showed lower LPA concentrations than controls or patients with AUD. In conclusion, our data suggest that LPA species could be potential biomarkers for SUD in women and men, which could contribute to a better stratification of these patients in treatment programs.
PB MPDI
SN 2076-3425
YR 2022
FD 2022
LK https://hdl.handle.net/20.500.14352/71617
UL https://hdl.handle.net/20.500.14352/71617
LA eng
NO Instituto de Salud Carlos III (ISCIII)/ FEDER/ Ministerio de Ciencia e Innovación
NO Instituto de Salud Carlos III/ FEDER
NO Delegación del Gobierno para el Plan Nacional sobre Drogas, Ministerio de Sanidad/FEDER
NO Junta de Andalucía/FEDER
DS Docta Complutense
RD 9 abr 2025